The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $4,422,803 were purchased by MCCORMICK FRANK on Jun 24 ’25. At $44.23 per share, MCCORMICK FRANK acquired 100,000 shares.
Also, Valantine Hannah sold 4,292 shares, netting a total of over 171,680 in proceeds. Following the sale of shares at $40.00 each, the insider now holds 1,764 shares.
Before that, HANNAH A VALANTINE had added 4,292 shares to its account. In a trade valued at $171,680, the Director bought BridgeBio Pharma Inc shares for $40.00 each.
As published in their initiating research note from Wolfe Research on June 17, 2025, BridgeBio Pharma Inc [BBIO] has been an Outperform and the price target has been revised to $49. Analysts at Redburn Atlantic started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of October 16, 2024, Scotiabank has initiated its “Sector outperform” rating for BBIO. Earlier on October 03, 2024, Oppenheimer initiated its rating. Their recommendation was “a Perform” for BBIO stock.
Analyzing BBIO Stock Performance
On last trading session,, BridgeBio Pharma Inc [NASDAQ: BBIO] plunged -0.16% to $44.38. The stock’s lowest price that day was $43.52, but it reached a high of $45.18 in the same session. During the last five days, there has been a surge of approximately 10.76%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 62.21%. Shares of the company reached a 52-week high of $45.18 on 06/25/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 43.51, which, if violated, would cause prices to drop to 42.65. In the upper region, resistance lies at 45.21. The next price resistance is at 46.05. RSI (Relative Strength Index) is 75.97 on the 14-day chart, showing overbought technical sentiment.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-05-30 dropping by -0.19 million shares to 21.99 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 22.18 million shares. A decline of -0.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.62 of the overall float, the days-to-cover ratio (short ratio) decline to 6.62.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 61.98% from the previous closing price of $44.45. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On September 04, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and initiated coverage with a $46.
